Lek Banned from Marketing Leading Drug in Croatia

Ljubljana, 1 October - Leading Slovenian pharmaceuticals company Lek will have to stop selling its drug Amlopin, used for high blood pressure treatment, on the Croatian market. The commercial court in Zagreb has issued a temporary order forbidding Lek's subsidiary, Lek Zagreb, to import and sell Amlopin in Croatia.